PROTAC GDI2 Degrader-1

• UNSPSC Description:

  PROTAC GDI2 Degrader-1 (compound 21) is a potent PROTAC GDI2 degrader. PROTAC GDI2 Degrader-1 exhibits excellent in vivo antitumor activity in the GDI2-overexpressing pancreatic xenograft models[1].

• Target Antigen:

  PROTACs

• Type:

  Reference compound

• Related Pathways:

  PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/protac-gdi2-degrader-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=CC(C)=CC(COC2=CC3=C([C@](C[C@](O)(CC4=CN(CCOCCOCCOCCNC([C@@H](CC(C)C)NC([C@@H](O)[C@H](N)CC5=CC=CC=C5)=O)=O)N=N4)C[C@@H]6C)([H])N6CC3)C=C2OCC7=CC(C)=CC(C)=C7)=C1

• Molecular Weight:

  1032.32

• References & Citations:

  [1]Yong Sun, et al. Targeting GDP-Dissociation Inhibitor Beta (GDI2) with a Benzo[a]quinolizidine Library to Induce Paraptosis for Cancer Therapy. JACS Au 2023, September 26, 2023

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported